cyrilzakka/clinical-trials huggingface dataset:
Trans-pulmonary Biomarkers in Pulmonary Hypertension

The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.

Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old
* Undergoing RHC for PH evaluation

Exclusion Criteria:

* Anemia defined as Hgb \< 10 g/dL and HCT \< 30
* Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure)
* Left ventricular ejection fraction ≤ 40%
* Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure)
* IPF, CTEPH, COPD/OSA as the dominant etiology of PH
* Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.
Assessment of Autogenous Dentin Graft in Treatment of Infra-bony Defect

The aim of the present study was to evaluate the effect of demineralized autogenous dentine on treatment of infrabony defects.

In this study, the investigators tested the effect of demineralized autogenous dentine as a bone graft in treatment of stage III periodontitis in term of probing pocket depth reduction, mean gain in clinical attachment level, and bone gain in defect sites.

Eligibility Criteria:
Inclusion Criteria:

* Patients with good systemic health and no contraindication for periodontal surgery.
* Patients who are able to maintain good oral hygiene.
* Gingival thickness for the site selected should be ≥1mm.
* Probing depth of ≥ 6mm.
* Patient has at least one hopeless teeth

Exclusion Criteria:

* Active infectious diseases (hepatitis, tubercu¬losis, HIV, etc....).
* Medically compromised patients.
* Smokers and alcoholic abusers
* People who suffer from any systemic disease that affect the periodontium.
* Pregnant, postmenopausal women.
* People who take anti-inflammatory drugs, anti¬biotics or vitamins within the previous 3 month.
* People who use mouth washes regularly
* Participants in other clinical trials.
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

This is a study using a parallel control approach and is expected to recruit 35 volunteers, including 8 prostate cancer patients, 8 neuroendocrine tumour patients, 8 glioma patients, 8 Parkinson's syndrome patients, and 3 normal volunteers, to undergo dual-nuclide PET/CT imaging and to validate the isolation effect and quantitative accuracy of simultaneous dual-nuclide imaging in humans.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18 \~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index \[BMI = weight (kg)/height 2 (m2)\] within the range of 19.0 \~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma: patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Parkinson's syndrome: patients with high clinical suspicion of Parkinson's syndrome.

Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.

Exclusion Criteria:

* Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Under 18 years of age or ECOG score \> 2; Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Women during pregnancy and breastfeeding; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Participation in other interventional clinical trials within 1 month prior to screening; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
Effects of Exergames on Vestibular Function in Healthy Community Dwellers.

The aim is to assess the effects of virtual reality-based intervention on vestibular functions in healthy community dwellers.

Elderly usually experience an age-related type of vestibular disorder, which involves vertigo, dizziness and poor postural stability. These symptoms seem to contribute to the "geriatric syndrome", which describes a complex symptomatology. It usually has multiple causes and must be considered interdisciplinary. This study will only consider healthy elderly with an expected age-related degeneration of the vestibular system. In terms of restoring vestibular functioning, compensation can be classified into adaptation, substitution and habituation. Adaptation enhances the Vestibulo-ocular reflex, which is equivalent to restoration. Habituation on the other hand, accustoms the affected person to a conflicting situation, in order that the response of the Vestibulo-ocular reflex is avoided. Substitution is distinguished in literature between sensory and behavioral, in which the sensorial substitution transfers the importance given to proprioceptive and visual inputs and the behavioral substitution refers to avoidance strategies e.g. immobilization, increased blink reflex and prevention of head rotations. Slower gait speed may also be a method used by elderly for compensation during a task when the base of support is unstable. Considering recommendation future studies should incorporate examinations of functional gaze stability during typical daily tasks in more familiar settings as opposed to laboratory assessments. Increased head movement may disturb balance and the risk of falling may be raised while walking stairs. As head stability is challenged during stair descent, elderly with age-related visual and vestibular impairment have problems with completing this quotidian task. A way to consider these observations in vestibular rehabilitation is the use of a virtual reality environment, which provides a motivating and pleasant method to train and that includes exercises requiring head turns. Successful use of virtual reality in rehabilitation of vestibular patients has previously been implemented. However, these studies did not particularly to exercise head turns by completing an orientation task.

Eligibility Criteria:
Inclusion Criteria:

Healthy community dwellers Adult male and female participant's (≥65 years) Signed informed consent after being informed

Exclusion Criteria:

Benign paroxysmal positional vertigo Acute pain Walking disability (independent walking \<10 meters) Uncontrolled cardiovascular disease (e.g.: uncontrolled blood pressure) Weakness due to neurological problems
The Th9/IL-9 and Early Enteral Nutrition in Sepsis

The investigators aim to evaluate the roles of Th9/IL-9 in the mechanisms of early enteral nutrition (EEN) maintaining intestinal mucosal barrier in sepsis. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis. In addition, the investigators also aim to evaluate the effects of different proportions of target total enteral nutrition on the prognosis of sepsis.


Eligibility Criteria:
Inclusion Criteria:

1. Clinical diagnosis of sepsis
2. Within 3 days of sepsis onset before ICU admission
3. No artificial nutrition (enteral or parenteral nutrition) were provided before ICU admission

Exclusion Criteria:

1. Ileus
2. Digestive tract hemorrhage
3. Inflammatory bowel disease
4. Abdominal hypertension (IAP \>25mmHg)
5. Cancer or chronic organ dysfunction (e.g., hepatic or renal dysfunction)
6. Malnutrition or immunodeficiency
7. Long-term use of hormones
Computer Modelling of the Cervical Spine Movements in Cervical Dystonia

Cervical dystonia (CD) is a syndrome characterized by sustained and/or phasic involuntary neck muscle activity causing abnormal head postures and movements. It is the most frequent form of adult focal dystonia. The distribution of dystonic muscles is unique for each patient, explaining the variety of patterns encountered.

The therapeutic management of CD is essentially local and symptomatic: Botulinum Neurotoxin injections and/or specific retraining therapy programmes. Therefore, analyzing the characteristics of abnormal head movements and identifying the dystonic muscles are the key points of these treatments.

To a better understanding of the posture and movement disorders of head and neck, we wish to establish a three-dimensional (3-D) computer model of cervical spine movements of ten healthy subjects built from images obtained with the "Cone Beam " system. Then we will compare the cervical posture and movements for each of ten CD patients matched in age and genre to the computer model. Comparison with patients' images in the axial plane reconstructed by computer with the 3-D computer model will lead to the description of various patterns of CD. Analysis of the musculoskeletal disturbances in CD should be a help to improve the localization of Botulinum Neurotoxin injection sites as well as retraining programmes.


Eligibility Criteria:
Inclusion Criteria:

* Tonic form of focal or segmental cervical dystonia (diagnostic confirmed by a neurologist specialized in movement disorders) for CD patients, or absence of CD for control subjects
* absence of treatment by botulinum neurotoxin, or last injection \> 3 months
* age \> 18 and \< 71 years
* informed consent
* medical insurance coverage

Exclusion Criteria:

* CD mobile (clonic) and/or head tremor
* patient unable to sit without moving the head during the examination (x-ray pictures with cone beam)
* Other neurological disease with effect on the posture and/or movement of the cervical region
* Pain or traumatism of the cervical region requiring medical or surgical treatment in the preceding 6 months
* Pregnant or breast feeding patient
* Participation in another research with a potential impact on evaluation criteria
* patient under judiciary protection
A Research Study for Latina Women With Breast Cancer

The purpose of this study is to examine the feasibility and preliminary efficacy of a psychosocial eHealth intervention designed to improve hormone therapy adherence among Hispanic/Latinx women with breast cancer. Our proposed secondary outcomes are health-related quality of life and self-efficacy in managing hormone therapy side effects.

The intervention components include breast cancer knowledge, hormone/endocrine therapy knowledge, stress awareness and management, social support, and enhanced communication and intimacy skills. The intervention will be delivered via a Smartphone application over a 12-week period.

All participants will receive the intervention application (described below). Aside from using the Smartphone application for the recommended 12 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), 6-week follow-up, and 12-week follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Diagnosis of breast cancer, non-metastatic, stage 0-III (A, B, or C)
* Receiving or received endocrine/hormone therapy within the last 3 years (36 months)
* At least 18 years of age
* Able to speak and read English or Spanish
* Able to provide informed consent
* Self-identify Hispanic/Latina ethnicity

Exclusion Criteria:

* Stage IV or metastatic
* Visual, hearing, voice, or motor impairment that would prevent completion of study procedures
* Diagnosis of an unmanaged psychotic disorder, bipolar disorder, dissociative disorder, or other diagnoses for which participation in this trial is either inappropriate or dangerous - this includes patients who have a life-threatening illness (e.g., end-stage kidney disease) or diagnosis of a chronic disease that is associated with a major functional impairment (e.g., fibromyalgia)
* Illicit substance or alcohol dependence
* Suicidal ideation, plan, intent
* Alzheimer's, dementia, or history of stroke
* Scheduled reconstruction surgery within 1 month of any study procedures or involvement.
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive Pulmonary Disease (COPD).


Eligibility Criteria:
Inclusion Criteria:

* COPD diagnosis define by ATS(American Thoracic Society)/ ERS (European Respiratory Society)
* Subjects of Asian ancestry
* Valid informed consent
* Current or former smoker
* \> or = 2 on the modified Medical Research Council Dyspnea Scale at Screening

Exclusion Criteria:

* Pregnancy
* A current diagnosis of asthma
* alpha1-antitrypsin deficiency as the underlying cause for COPD
* Other active, respiratory disorders
* Have lung volume reduction surgery within 12 months prior to Screening
* A chest X-ray or CT (Computerised Tomography) scan reveals evidence of clinical significant abnormalities not believed to be due to the presence of COPD
* Poorly controlled COPD: acute worsening of COPD managed by corticosteroids, antibiotics, or treatments prescribed by a physician 6 weeks prior to Screening, or requires hospitalisation due to poorly controlled COPD 12 weeks prior to Screening
* Lower respiratory tract infection requires antibiotics within 4 weeks prior to Screening
* Other disease or abnormalities, in the opinion of the investigator, would put the safety of the subject at risk during the study or would affect safety or efficacy analysis if the disease/condition exacerbated during the study
* Subject with carcinoma that has not been in complete remission for at least 5 years, carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
* Subject has a history of hypersensitivity to any of the study medications or components of the inhalation powder. Subject has a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded.
* Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years prior to Screening
* Subjects who are medically unable to withhold albuterol, ipratropium for 4 hrs and/or theophylline for 12 hrs prior to spirometry testing.
* Subjects use a list of prohibited medications specified in the study protocol, including but not limited to traditional or herbal medications for the treatment of COPD
* Subject requires long-term oxygen therapy or nocturnal oxygen therapy for greater than 12 hours a day
* Pulmonary rehabilitation: subjects who are in the maintenance phase are not excluded.
* Non-compliance
* Questionable validity of the Informed Consent
* Prior use of study medication or other investigational drugs
* Affiliation with investigator site
Simplification and Implementation of Awake Fibreoptic Orotracheal Intubation

Awake fibreoptic intubation (AFOI) is a classic and standard method for some special patients which is also difficult for anesthesiologists to learn and master. The procedure is sometimes hard and often takes about 20-30 min. Most of patients have a strong sense of discomfort. Investigators conducted the research to study the simplification and feasibility of AFOI.

Many studies have studied the sedative drugs and regional anesthesia related to awake intubation. However, several problems of AFOI are existing including long operation time, patients' strong discomfort, coughing and resistance. And, to investigators' knowledge, there was a lack of a fixed procedure for the implementation of AFOI. Investigators conducted the research and aimed to study the simplification and feasibility of a new AFOI method based on years of clinical theory, practice and experience.

Eligibility Criteria:
Inclusion Criteria:

1. American Society of Anesthesiologists' physical status I-II patients
2. Aged 18-75 years
3. Mallampati Grade I-II
4. Body Mass Index 18.5-28 kg·m-2

Exclusion Criteria:

1. Allergic to the drugs involved in the study
2. Neck mass or infection
3. Drug or alcohol abuse
4. Pregnant
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of aRCC.
* Patients aged ≥18 years at aRCC diagnosis treated with a 1L IO containing combination therapy who have progressed to a 2L treatment.

Exclusion Criteria:

* Patient's hospital medical records are unavailable for review;
* Patients have started a 2L treatment as part of a Renal Carcinoma Treatment (RCT).
Assessment of the Efficacy of Vitamin D-fortified Bread in Healthy Adults

The aim of this study is to evaluate the efficacy of daily intake of fortified bread with vitamin D on serum 25-hydroxyvitamin D level, glycemic and lipidemic status in healthy subjects compared to vitamin D supplement.

Sixty apparently healthy subjects will be selected. Participants who are receiving vitamin D, calcium or omega-3 supplements within the last three months will be excluded. Subjects will be assigned randomly to one of the three intervention groups: 1.fortified bread+placebo,2. plain bread+vitamin D supplements,3. plain bread+placebo. Each participant will consume 50 g of bread and supplement or placebo every day for 2 months.

At the first and last visits, dietary and laboratory assessments will be performed for all subjects. Primary outcomes are improvement in vitamin D status and secondary outcome is improvement of glycemic and lipidemic markers and prevention of problems related to hypovitaminosis D.

Eligibility Criteria:
Inclusion Criteria:

* 20 to 50 years
* healthy subjects
* no receiving vitamin D or omega-3 supplement in past 3 months

Exclusion Criteria:

* receiving vitamin D or omega-3 supplement during the study
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study

Quetiapine (Seroquel ®), an atypical antipsychotic registered for use in schizophrenia, which has a very low propensity of extrapyramidal and endocrine side-effects, has also been studied as an adjunct in OCD. In an open trial, ten patients with OCD who had not responded to at least three previous treatments with a SRI at maximum dose and duration were assigned to receive quetiapine in addition to a SRI for 8 weeks. Given the efficacy of quetiapine in treatment resistant patients, and given its rapid onset of action (4-6 weeks), it is postulated that the combination of a low dose atypical antipsychotic and a standard dosage of an SRI as a treatment for patients with OCD might increase the number of responders as well as the effect size.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Eligibility Criteria:
Inclusion Criteria:

* All patients meet the DSM IV criteria for obsessive-compulsive disorder
* Y-BOCS score \> 16 if obsessions and compulsions
* Y-BOCS score \> 10 if only obsessions
* Y-BOCS score \> 10 if only compulsions
* Male and female, aged between 18-70 years
* Female patients of childbearing potential must have a negative pregnancy test and use a reliable method of contraception.
* Written informed consent

Exclusion Criteria:

* Presence of any of the following DSM IV conditions; major depression (with a HDRS\>15, \[17 item\]), bipolar disorder, schizophrenia or any other psychotic condition, tic disorder, substance related disorder during the past 6 months, epilepsy, or any structural CNS disorder or stroke within the last year.
* Evidence of clinically significant and unstable cardiovascular, gastro-intestinal, pulmonary, renal, hepatic, endocrine or haematological disorders, glaucoma, myocardial infarction within the past year, or micturition abnormalities
* Patients at risk for suicide
* Multiple serious drug allergies or known allergy for the trial compounds
* Use of antipsychotics during 6 months before the screening visit
* Use of any other psychotropic drug during 6 months before the screening visit
* Cognitive and behavioural treatment 3 months prior to the screening visit
* Any known contra-indication against citalopram or quetiapine